Grail, Inc. (GRAL) Stock Price & Analysis
Grail, Inc. (GRAL) fell 1.01% to USD 60.9 as of June 10, 2026 at 07:15 UTC, according to Nexqual real-time market data.
GRAL last closed at USD 61.52; the session ranged USD 57.79–63.05 on volume of 545,534 shares. Market capitalization is $2.61B, with a 52-week range of USD 29.95–118.84 (NMS). Source: Nexqual, June 10, 2026 at 07:15 UTC.
Key Statistics (as of June 10, 2026 at 07:15 UTC)
| Price | USD 60.9 |
|---|---|
| Change | ▼ 1.01% (down) |
| Previous Close | USD 61.52 |
| Open | USD 63.05 |
| Day Range | USD 57.79 – 63.05 |
| 52-Week Range | USD 29.95 – 118.84 |
| Volume | 545,534 shares |
| Market Cap | $2.61B |
| Exchange | NMS |
Technical Analysis (GRAL)
Nexqual's technical model rates GRAL "NEUTRAL" based on 3 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 07:15 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 50.06 (neutral) |
| vs SMA50 | Above (USD 57.2) |
| MACD | 1.48 (positive) |
Analyst Ratings (GRAL)
Wall Street analysts rate GRAL "Buy" based on 8 analysts, with a mean price target of USD 66 (range USD 56–80), per Nexqual as of June 10, 2026 at 07:15 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 66 |
| High Target | USD 80 |
| Low Target | USD 56 |
| Buy / Hold / Sell | 4 / 5 / 0 |
Earnings (GRAL)
| Next Earnings Date | 2026-05-05 |
|---|---|
| EPS Estimate | USD -2.41 |
| Revenue Estimate | $42.77M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.37 vs est -1.96 ▲ beat |
| 2025-12-31 | USD -2.44 vs est -2.53 ▲ beat |
| 2025-09-30 | USD -2.46 vs est -3.27 ▲ beat |
| 2025-06-30 | USD -3.18 vs est -3.56 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:15 UTC.
Financials & Fundamentals (GRAL)
| Total Revenue | $156.12M |
|---|---|
| Revenue Growth (YoY) | +28.10% |
| Gross Margin | +49.28% |
| Operating Margin | -332.88% |
| Profit Margin | -253.22% |
| ROE | -16.09% |
| Debt / Equity | 2.04 |
| Current Ratio | 11.74 |
| Total Cash | $823.11M |
| Total Debt | $51.03M |
| Free Cash Flow | $-107.75M |
Source: Nexqual, June 10, 2026 at 07:15 UTC.
Financial Health Score (GRAL)
Nexqual rates Grail, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 07:15 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $823M cash vs $51M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$108M, burning cash |
| Efficiency | Critical — ROE -16%, ROA -11.4% |
Ownership (GRAL)
| Insider Ownership | +5.17% |
|---|---|
| Institutional Ownership | +83.58% |
| Shares Outstanding | 42.92M |
| Float | 33.53M |
| Short % of Float | +15.06% |
Source: Nexqual, June 10, 2026 at 07:15 UTC.
Leadership (GRAL)
Grail, Inc. is led by Joshua J. Ofman M.D., M.S.H.S (age 60), CEO, President & Director, per Nexqual as of June 10, 2026 at 07:15 UTC.
| CEO, President & Director | Joshua J. Ofman M.D., M.S.H.S (age 60) |
|---|---|
| Chief Financial Officer | Aaron Freidin (age 46) |
| Senior Vice President of Global Development & Operations | Paul Ciccolella |
| Chief Scientific Officer & President International | Harpal S. Kumar M.A., M.B.A., MEng |
Major Backers & Investors (GRAL)
Notable institutional backers of Grail, Inc. include Baker Bros. Advisors, LP, Farallon Capital Management LLC, Primecap Management Company, according to Nexqual as of June 10, 2026 at 07:15 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 9.39% |
| Farallon Capital Management LLC | 7.58% |
| Primecap Management Company | 4.3% |
| Deep Track Capital, Lp | 4.01% |
| Sessa Capital IM, L.P. | 4.01% |
| Morgan Stanley | 3.8% |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 3.05% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.15% |
| Vanguard Group | 7.82% |
| State Street | 7.12% |
Source: Nexqual, June 10, 2026 at 07:15 UTC.
From Grail, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- The law included certain standards, including that Centers for Medicare and Medicaid Services ("CMS") would establish coverage through a national coverage determination ("NCD") process under "reasonable and necessary" evidentiary requirements.
- We can leverage our proprietary platform for additional applications, including our precision oncology portfolio.
- The commercial opportunity for Galleri is significant, with more than 300 million individuals globally over the age of 50 (our intended use population), including more than 100 million individuals in the United States.
- Our proprietary targeted methylation platform, as well as our growing body of clinical and real-world data, have provided us with unique insights into cancer biology that enable development of products beyond asymptomatic screening.
Partnerships
- We have also begun entering select international markets through distributor partners, including Israel and Canada, and intend to enter South Korea through our partnership with Samsung.
- Under our agreement with the NHS, these results have met certain success criteria and missed others.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WGS | GeneDx Holdings Corp. | USD 56.33 | ▲ 7.89% |
| RVMD | Revolution Medicines, Inc. | USD 149.55 | ▲ 0.21% |
| NTRA | Natera, Inc. | USD 222.82 | ▲ 3.49% |
| GH | Guardant Health, Inc. | USD 130.12 | ▲ 3.59% |
| GPCR | Structure Therapeutics Inc. | USD 41.25 | ▲ 9.77% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:15 UTC. This page is informational and not investment advice.